Ruth ORegan
Ruth ORegan
Verified email at
Cited by
Cited by
Emerging use of nanoparticles in diagnosis and treatment of breast cancer
MV Yezhelyev, X Gao, Y Xing, A Al-Hajj, S Nie, RM O'Regan
The lancet oncology 7 (8), 657-667, 2006
Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology
WJ Gradishar, BO Anderson, J Abraham, R Aft, D Agnese, KH Allison, ...
Journal of the National Comprehensive Cancer Network 18 (4), 452-478, 2020
The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy
Z Mitri, T Constantine, R O'Regan
Chemotherapy research and practice 2012, 2012
Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry
Y Xing, Q Chaudry, C Shen, KY Kong, HE Zhau, LW Chung, JA Petros, ...
Nature protocols 2 (5), 1152-1165, 2007
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
F André, R O'Regan, M Ozguroglu, M Toi, B Xu, G Jerusalem, N Masuda, ...
The lancet oncology 15 (6), 580-591, 2014
Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA
MJ Lund, KF Trivers, PL Porter, RJ Coates, B Leyland-Jones, OW Brawley, ...
Breast cancer research and treatment 113, 357-370, 2009
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
E Paplomata, R O’Regan
Therapeutic advances in medical oncology 6 (4), 154-166, 2014
Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging
MV Yezhelyev, L Qi, RM O’Regan, S Nie, X Gao
Journal of the American Chemical Society 130 (28), 9006-9012, 2008
Triple-negative breast cancer in African-American women: disparities versus biology
EC Dietze, C Sistrunk, G Miranda-Carboni, R O'regan, VL Seewaldt
Nature Reviews Cancer 15 (4), 248-254, 2015
NCCN guidelines insights: breast cancer, version 1.2017
WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ...
Journal of the National Comprehensive Cancer Network 15 (4), 433-451, 2017
Insulin-like growth factor-I–dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells
TR Graham, HE Zhau, VA Odero-Marah, AO Osunkoya, KS Kimbro, ...
Cancer research 68 (7), 2479-2488, 2008
Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer
X Li, J Yang, L Peng, AA Sahin, L Huo, KC Ward, R O’Regan, MA Torres, ...
Breast cancer research and treatment 161, 279-287, 2017
Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology
WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ...
Journal of the National Comprehensive Cancer Network 16 (3), 310-320, 2018
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a …
A Di Leo, S Johnston, KS Lee, E Ciruelos, PE Lønning, W Janni, ...
The Lancet Oncology 19 (1), 87-100, 2018
Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial
NU Lin, V Borges, C Anders, RK Murthy, E Paplomata, E Hamilton, ...
Journal of Clinical Oncology 38 (23), 2610, 2020
Quantum dots for human mesenchymal stem cells labeling. A size-dependent autophagy activation
O Seleverstov, O Zabirnyk, M Zscharnack, L Bulavina, M Nowicki, ...
Nano letters 6 (12), 2826-2832, 2006
In situ molecular profiling of breast cancer biomarkers with multicolor quantum dots
MV Yezhelyev, A Al‐Hajj, C Morris, AI Marcus, T Liu, M Lewis, C Cohen, ...
Advanced Materials 19 (20), 3146-3151, 2007
Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice
K Yao, ES Lee, DJ Bentrem, G England, JIMG Schafer, RM O’Regan, ...
Clinical Cancer Research 6 (5), 2028-2036, 2000
Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.
F Andre, M Campone, R O'Regan, C Manlius, C Massacesi, T Sahmoud, ...
J Clin Oncol, 2009
Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth …
NK Saxena, LT Taliaferro-Smith, BB Knight, D Merlin, FA Anania, ...
Cancer research 68 (23), 9712-9722, 2008
The system can't perform the operation now. Try again later.
Articles 1–20